Clinical Trials Browser

Phase 2 × tocilizumab × 1 year × Clear all

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Active not recruiting

71 enrolled 9 charts

Melanoma

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Phase 2 Active not recruiting

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT05207670 2026-03-05

MorningSun

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT05233397 2026-03-02

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Phase 2 Recruiting

Craniopharyngioma

NCT05972135 2026-02-23

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

Cytokine Release Syndrome, Multiple Myeloma

NCT04375228 2026-02-06

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

Phase 2 Active not recruiting

Other solid neoplasm

Immune-related Adverse Events

NCT06043674 2026-01-07

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04395222 2026-01-06

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Phase 2 Active not recruiting

21 enrolled 15 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT04729959 2025-10-20

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Phase 2 Active not recruiting

Astrocytoma, Glioblastoma

NCT04377659 2025-05-28

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Phase 2 Terminated

9 enrolled 8 charts

COVID-19, Respiratory Tract Infections

NCT03821246 2025-05-15

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Phase 2 Recruiting

Prostatic Neoplasms

NCT03434730 2025-04-22

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Phase 2 Completed

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases